Evidence map›Paper›PMID 34854253›Full record

ArticleCancer medicine2022

Better effect of intrapleural perfusion with hyperthermic chemotherapy by video-assisted thoracoscopic surgery for malignant pleural effusion treatment compared to normothermic chemoperfusion of the pleural cavity.

Yejun Cao, Qiying Zhang, Zhiyuan Huang, Zhengjun Chai, Jie Liu, Jinyi Wang, Zhengliang Sun, Tian Zhao, Guangxue Wang, Guohan Chen and 3 more

Open access · goldAbstract readCase ReportsComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
0.6field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it, 6 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Lymph nodes rather than pleural metabolic activity inTranslational lung cancer research · 2024
    Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 1 institution in 2 countries.

Yejun CaoDepartment of Thoracic Surgery, Tongji University School of Medicine, Shanghai East Hospital Affiliated to Tongji University, Shanghai, China.ORCID 0000-0003-0474-3066
Qiying ZhangDepartment of Thoracic Surgery, Tongji University School of Medicine, Shanghai East Hospital Affiliated to Tongji University, Shanghai, China.
Zhiyuan HuangResearch Center for Translational Medicine, Tongji University School of Medicine, Shanghai East Hospital Affiliated to Tongji University, Shanghai, China.ORCID 0000-0001-9023-5302
Zhengjun ChaiDepartment of Thoracic Surgery, Tongji University School of Medicine, Shanghai East Hospital Affiliated to Tongji University, Shanghai, China.
Jie LiuDepartment of Thoracic Surgery, Tongji University School of Medicine, Shanghai East Hospital Affiliated to Tongji University, Shanghai, China.
Jinyi WangDepartment of Thoracic Surgery, Tongji University School of Medicine, Shanghai East Hospital Affiliated to Tongji University, Shanghai, China.
Zhengliang SunDepartment of Thoracic Surgery, Tongji University School of Medicine, Shanghai East Hospital Affiliated to Tongji University, Shanghai, China.
Tian ZhaoDepartment of Thoracic Surgery, Tongji University School of Medicine, Shanghai East Hospital Affiliated to Tongji University, Shanghai, China.
Guangxue WangResearch Center for Translational Medicine, Tongji University School of Medicine, Shanghai East Hospital Affiliated to Tongji University, Shanghai, China.
Guohan ChenDepartment of Thoracic Surgery, Tongji University School of Medicine, Shanghai East Hospital Affiliated to Tongji University, Shanghai, China.
Yang HanDepartment of Pathology, Tongji University School of Medicine, Shanghai East Hospital Affiliated to Tongji University, Shanghai, China.
Qinchuan LiDepartment of Thoracic Surgery, Tongji University School of Medicine, Shanghai East Hospital Affiliated to Tongji University, Shanghai, China.
Xuan HongDepartment of Thoracic Surgery, Tongji University School of Medicine, Shanghai East Hospital Affiliated to Tongji University, Shanghai, China.
Tongji University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveThe aim of this study was to assess the efficacy and safety of intrapleural perfusion with hyperthermic chemotherapy (IPHC) in treating malignant pleural effusion (MPE) compared to normothermic chemoperfusion of the pleural cavity (NCPC), and to investigate the better treatment to control MPE.

methodsMalignant pleural effusion patients were enrolled in the study and treated with NCPC or IPHC under video-assisted thoracoscopic surgery (VATS). The chest drainage duration, clinical characteristics, and recurrence time of pleural effusion of patients were collected for statistical analysis. The chi-squared test and the Fisher's exact test were applied to compare the distribution differences in categorical variables. Progression-free survival (PFS) was estimated by the Kaplan-Meier method and was compared by the log-rank test. The survival analysis was performed using the Cox proportional hazards method.

resultsA total of 37 MPE patients were enrolled in this study. Twenty-seven patients received NCPC and 10 patients received IPHC under VATS. Significant differences were found in pathological types (p = 0.011), chest drainage duration (p = 0.005), and remission rate (p = 0.009) between two different treatment groups. The chest drainage duration of IPHC under VATS was shorter than the NCPC group (t = 2.969, p = 0.005). The remission rate of MPE in IPHC group was better than the NCPC one (OR = 0.031, 95% CI: 0.002-0.507, p = 0.015). The result of the Kaplan-Meier method showed that IPHC group could significantly prolong the PFS of patients with MPE compared to NCPC group (log-rank p = 0.002). Univariate cox regression analysis showed that patients with MPE in the IPHC group presented significant longer PFS than the NCPC group (HR = 0.264, 95% CI: 0.098-0.713, p = 0.009). Multivariate cox regression analysis further verified this conclusion (HR = 0.268, 95% CI: 0.096-0.753, p = 0.012).

conclusionCompared to the NCPC, the IPHC under VATS presents a better control effect on MPE, shorter tube placement time, and longer complete remission time. For this reason, we recommend IPHC under VATS as the first-line treatment for patients with MPE those who can tolerate minimally invasive surgery.

Indexed as

Hyperthermia, InducedThoracic Surgery, Video-AssistedAgedAntineoplastic AgentsFemaleHumansKaplan-Meier EstimateMaleMiddle AgedPerfusionPleural CavityPleural Effusion, MalignantProportional Hazards ModelsTreatment OutcomeAntineoplastic Agentscurative effectintrapleural perfusion with hyperthermic chemotherapy (IPHC)malignant pleural effusion (MPE)normothermic chemoperfusion of the pleural cavity

Identifiers

PMID34854253
PMCPMC8729049
OpenAlexW3214793499

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.